Literature DB >> 17674018

Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone.

Ilse Krebs1, Katharina Krepler, Ulrike Stolba, Alexandra Goll, Susanne Binder.   

Abstract

BACKGROUND: The objective of the study was to investigate whether combined treatment with photodynamic therapy (PDT) and triamcinolone acetonide intravitreally applied is superior to PDT alone in eyes with retinal angiomatous proliferation (RAP).
METHODS: Between July 2004 and June 2005 eyes with RAP in age-related macular degeneration were included in a prospective study and were treated with 4 mg of triamcinolone acetonide followed by PDT (group 1). Eyes with RAP treated with PDT alone before June 2004 were retrospectively reviewed (group 2). Distance visual acuity (VA) with Early Treatment Diabetic Retinopathy Study (ETDRS) charts, greatest diameter of the lesion (measured by fluorescein angiography), and retinal thickness (measured by optical coherence tomography) were performed at baseline and at 6 weeks, 3 months, 6 months and 12 months thereafter.
RESULTS: Fifty-eight eyes in 58 patients were included: 27 eyes in the combined treatment group and 31 eyes in the PDT monotherapy group. The groups were comparable with regard to age, gender and RAP stage. VA decreased from 65.6 to 52.0 and from 60.7 to 44.0 letters, and lesion size increased from 3.2 mm to 3.5 mm and from 3.3 mm to 3.5 mm in the combined and monotherapy groups respectively. There was a trend towards a better outcome in the combined group. Significantly (p = 0.01) fewer complications occurred in the combined group (22.2%) than in the monotherapy group (54.8%).
CONCLUSION: No significant differences could be found in the time course of distance VA, retinal thickness, and lesion size between the PDT monotherapy group and the combined PDT and IVTA group. However, significantly fewer complications occurred in the combined treatment group. New therapeutic strategies might be required in RAP lesions, probably including therapy with anti-angiogenic agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17674018     DOI: 10.1007/s00417-007-0651-0

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  32 in total

1.  Transplantation of autologous retinal pigment epithelium in eyes with foveal neovascularization resulting from age-related macular degeneration: a pilot study.

Authors:  Susanne Binder; Ulrike Stolba; Ilse Krebs; Lukas Kellner; Christian Jahn; Hans Feichtinger; Margit Povelka; Ursula Frohner; Andreas Kruger; Ralf-Dieter Hilgers; Walter Krugluger
Journal:  Am J Ophthalmol       Date:  2002-02       Impact factor: 5.258

2.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2.

Authors:  Neil M Bressler
Journal:  Am J Ophthalmol       Date:  2002-01       Impact factor: 5.258

3.  Retinal pigment epithelial tears after pegaptanib injection for exudative age-related macular degeneration.

Authors:  Rishi P Singh; Jonathan E Sears
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

4.  The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy.

Authors:  D B Chandler; G Rozakis; E de Juan; R Machemer
Journal:  Am J Ophthalmol       Date:  1985-06-15       Impact factor: 5.258

5.  Retinal pigment epithelial tear following intravitreal pegaptanib sodium.

Authors:  Mandeep Singh Dhalla; Kevin J Blinder; Asheesh Tewari; Seenu M Hariprasad; Rajendra S Apte
Journal:  Am J Ophthalmol       Date:  2006-04       Impact factor: 5.258

6.  Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration.

Authors:  Albert J Augustin; Ursula Schmidt-Erfurth
Journal:  Am J Ophthalmol       Date:  2006-04       Impact factor: 5.258

7.  Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration.

Authors:  C H Meyer; S Mennel; J C Schmidt; P Kroll
Journal:  Br J Ophthalmol       Date:  2006-09       Impact factor: 4.638

8.  Unfavorable effect of photodynamic therapy for late subretinal neovascularization with chorioretinal anastomoses associated with idiopathic multiple serous detachments of the retinal pigment epithelium.

Authors:  M Fossarello; E Peiretti; I Zucca; A Serra
Journal:  Eur J Ophthalmol       Date:  2004 Nov-Dec       Impact factor: 2.597

9.  Sequence of early vascular events after photodynamic therapy.

Authors:  Stephan Michels; Ursula Schmidt-Erfurth
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-05       Impact factor: 4.799

10.  Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration.

Authors:  J S Slakter; L A Yannuzzi; U Schneider; J A Sorenson; A Ciardella; D R Guyer; R F Spaide; K B Freund; D A Orlock
Journal:  Ophthalmology       Date:  2000-04       Impact factor: 12.079

View more
  8 in total

1.  Treatment of recurrent retinal angiomatous proliferation with intravitreal triamcinolone acetonide followed by photodynamic therapy with verteporfin: A retrospective case series.

Authors:  Nicola Cardascia; Claudio Furino; Andrea Ferrara; Francesco Boscia; Giovanni Alessio
Journal:  Curr Ther Res Clin Exp       Date:  2009-06

2.  [Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections].

Authors:  M Maier; C Perz; J Bockmaier; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

3.  Visual outcome of photodynamic therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5 years of follow-up.

Authors:  Akiko Miki; Shigeru Honda; Hiroshi Kojima; Masaya Nishizaki; Tomoko Nagai; Masashi Fujihara; Mamoru Uenishi; Mihori Kita; Yasuo Kurimoto; Akira Negi
Journal:  Jpn J Ophthalmol       Date:  2013-03-19       Impact factor: 2.447

4.  Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan.

Authors:  Shigeru Honda; Yasuo Kurimoto; Yasuaki Kagotani; Hiroyuki Yamamoto; Hitoshi Takagi; Mamoru Uenishi
Journal:  Jpn J Ophthalmol       Date:  2009-12-18       Impact factor: 2.447

5.  One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation.

Authors:  Yukari Shirakata; Chieko Shiragami; Ayana Yamashita; Eri Nitta; Atsushi Fujiwara; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2012-09-19       Impact factor: 2.447

6.  Effect of photodynamic therapy (PDT), posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatous proliferation.

Authors:  Saya Nakano; Shigeru Honda; Hideyasu Oh; Mihori Kita; Akira Negi
Journal:  Clin Ophthalmol       Date:  2012-02-20

7.  The effect of triamcinolone acetonide on laser-induced choroidal neovascularization in mice using a hypoxia visualization bio-imaging probe.

Authors:  Shinsuke Takata; Tomomi Masuda; Shinsuke Nakamura; Takahiro Kuchimaru; Kazuhiro Tsuruma; Masamitsu Shimazawa; Hideko Nagasawa; Shinae Kizaka-Kondoh; Hideaki Hara
Journal:  Sci Rep       Date:  2015-04-30       Impact factor: 4.379

8.  Effects of triamcinolone acetonide on vessels of the posterior segment of the eye.

Authors:  Fatemeh Valamanesh; Marianne Berdugo; Florian Sennlaub; Michèle Savoldelli; Cyndie Goumeaux; Marianne Houssier; Jean-Claude Jeanny; Alicia Torriglia; Francine Behar-Cohen
Journal:  Mol Vis       Date:  2009-12-08       Impact factor: 2.367

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.